SCHEMBL7120749

SCHEMBL7120749

COc1cccc(CNC(=O)C2=CNc3c(c(=O)n(Cc4ccccc4)c(=O)n3C)S2(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
TP53 P04637 5/20 0.45
RXFP1 Q9HBX9 3/20 0.45
NR3C2 P08235 1/20 0.45
ALDH1A1 P00352 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MMP13 P45452 1/20 0.43
RAB9A P51151 1/20 0.43
TOP2A P11388 1/20 0.43
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42
PLK4 O00444 1/20 0.42
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
PDPK1 O15530 1/20 0.42
DAPK3 O43293 1/20 0.42
DYRK3 O43781 1/20 0.42
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118476 0.86 MMP1 (0.43) MAPTTP53RXFP1ALDH1A1SMN1; SMN2
SCHEMBL7121978 0.84 TRPA1 (0.50) MAPTALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL6685134 0.81 MAPT (0.49) MAPTTP53RXFP1NR3C2ALDH1A1
SCHEMBL7058428 0.80 SMN1; SMN2 (0.44) MAPTALDH1A1SMN1; SMN2MMP13RAB9A
SCHEMBL7115636 0.78 KMT2A (0.49) MAPTTP53RXFP1NR3C2ALDH1A1
SCHEMBL7114826 0.75 TRPA1 (0.40) ALDH1A1HTTSMN1; SMN2KDM4E
SCHEMBL6682687 0.75 MAPT (0.46) MAPTTP53RXFP1NR3C2ALDH1A1
SCHEMBL6474162 0.74 MAPT (0.56) MAPTTP53RXFP1NR3C2ALDH1A1
SCHEMBL6680234 0.73 MAPT (0.48) MAPTTP53RXFP1NR3C2ALDH1A1
SCHEMBL7120798 0.73 MAPT (0.49) MAPTTP53RXFP1NR3C2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224951-A1 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP25 MAPT 1473/4885TP53 2986/4885RXFP1 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.